A microfluidic assay was developed for screening botulinum neurotoxin serotype A (BoNT-A) by using a fluorescent resonance energy transfer (FRET) assay. Molded silicone microdevices with integral valves, pumps, and reagent reservoirs were designed and fabricated. [1] [2] [3] [4] Electrical and pneumatic control hardware were constructed, and software was written to automate the assay protocol and data acquisition. Detection was accomplished by fluorescence microscopy. The system was validated with a peptide inhibitor, running 2 parallel assays, as a feasibility demonstration. The small footprint of each bioreactor cell (0.5 cm 2 ) and scalable fluidic architecture enabled many parallel assays on a single chip. The chip is programmable to run a dilution series in each lane, generating concentration-response data for multiple inhibitors. The assay results showed good agreement with the corresponding experiments done at a macroscale level. Although the system has been developed for BoNT-A screening, a wide variety of assays can be performed on the microfluidic chip with little or no modification. (Journal of Biomolecular Screening 2005:788-794) 
INTRODUCTION
D ETECTION AND DIAGNOSIS of a biological threat are critical in the path of effective antidote development. The present effort is a step toward developing massively parallel arrays, of multiplexed (for assays as well as for detection) microfluidic devices, for use in routine drug screening as well as for highly sensitive biothreat detection and diagnostics platforms. Botulinum neurotoxins (BoNT types A-G) are Zn-metalloproteases, secreted from Clostridium botulinum. 5 These enzymes are known to cleave and inactivate cellular proteins involved in neurotransmission, resulting in fatal paralysis in human beings. A large body of research exists on the mechanistic and structural aspects of these neurotoxins. [6] [7] [8] Due to the severity and fatality associated with neurotoxin exposure, it is important to develop methods to find potential inhibitors for BoNT. Small-molecule inhibitors of BoNT-A have been reported recently. 9 This report focuses on the development of an ultra-miniaturized assay platform for toxin bioassays and detection.
In the past decade, miniaturization has become a standard for developing rapid, robust, and ultra-high-throughput assays for drug discovery and development. Significant advances have been made in various aspects of assay miniaturization, including reagent handling, distribution, reaction optimization, and finally, detection at highly sensitive levels. Standard microplates replaced microfuge tubes as vessels of choice and were in turn supplanted with higher density, but still templated, plates of a standard footprint. However, in recent years, advances in microfluidic technologies, coupled with highly sensitive fluorescence methodologies, have allowed development of microfluidic chips capable of conducting complex biological assays.
The following is a description of the development of a microfluidic platform, consisting of 3 parts: (1) polydimethylsiloxane (PDMS) microfluidic devices were designed, developed, and fabricated following established procedures; (2) BoNT assays were miniaturized and inhibition assays were conducted; and (3) reactions were detected using fluorescence microscopy. The goal was to develop a microfluidic platform for screening potential inhibitors against BoNT activity. The assay was first produced in macroscale and then integrated to the microfluidic device. Assay chemistry was developed in parallel, with the microfluidic device development and support hardware and software development. Finally, the 3 subsystems were successfully merged to form a complete microfluidic assay platform. The results presented in this report are the first of its kind in conducting, at subminiaturization
Microfluidic device development
A series of 3 devices, designated VALVE1, MIX1, and MIX2, was designed and tested. The results of 1 device was used as a guide for the next, leading to a more complex design. All the devices had integral pinch valves; 3 closely spaced pinch valves formed a peristaltic pump. The valves were used to control the flow of reagents from the on-chip reservoirs. The pumps were used to force a pair of reagent plugs around a loop to mix them. Two reaction loops were cascaded to perform a 2-step inhibition assay in the MIX2 device. This device runs 2 assays in parallel, with 1 set of controls demonstrating the scalable architecture.
Fabrication. The PDMS microdevices consisted of a 3-layer construction of PDMS/PDMS/glass. The top layer incorporated pneumatic control channels. Liquid channels were defined in the middle PDMS layer, whereas the bottom glass layer sealed the device and provided the optical detection window and mechanical support.
In the fabrication process, the air and liquid layer mask artwork were printed on Mylar with an 8000-dpi laser printer. Photoresist was spin coated onto 4-inch glass (liquid layer) and silicon wafers (air layer), exposed, and stripped to produce molds. The photoresist (for the liquid layer) was baked to soften the profile. The thick PDMS layer was cast for air channels using a 4-inch silicon wafer mold. The thin PDMS middle layer for liquid channels was then spin coated, partially cured, and bonded to the thick PDMS layer. The bonded device was removed from the liquid layer mold, and liquid and pneumatic access holes were incorporated. Finally, the PDMS device was bonded to glass. VALVE1 device. Initial fabrication experiments in molding, spin coating, bonding, and punching were carried out to develop the multilayer chip approach. The first functional device, VALVE1, consisted of a grid of variously sized vertical liquid channels (40-240 µm) and horizontal pneumatic channels (40-210 µm). This design yielded multiple valve configurations for determining optimum parameters. Nitrogen gas was used to pressurize the reagent reservoirs for liquid transport and for actuating pneumatic valves.
MIX1 device. The MIX1 device was developed to demonstrate the mixing and reaction loop concept. Filling, reservoir pumping, valve operation, pumping speeds, and mixing measurements were made to optimize its performance. Finally, hydrolysis of the fluorescent substrate by the recombinant LC-A was demonstrated on the chip. The layout of the chip is shown in Figure 1 . Five nanoliters of each of the 2 reagents was loaded into the reaction loop on the chip, and an on-chip pump was used to mix reagents. The device was mounted on an Olympus IX-70 microscope equipped with a Princeton Instruments cooled CCD camera for fluorescence detection.
MIX2 device. This chip was developed to demonstrate parallel, scalable microfluidic BoNT inhibition assays. The layout of the 64 × 32-mm device is shown in Figure 2a . A detailed view showing the center of the chip with the critical components is shown in Figure 2b. In the present configuration, the device can perform 2 assays simultaneously from independent reagent wells. One set of pneumatic control lines operated both assays synchronously. Each assay lane was composed of a large mixing loop (20 nL) at the bottom feeding a smaller mixing loop (5 nL).
Device control hardware and software. A data acquisition and control system was developed for operating the assay device. The system used a Windows 2000 PC with a high-speed serial board for transferring data from the cooled CCD camera that was mounted on the microscope. The system also controlled an electromagnetic shutter on the xenon arc lamp illuminator. The solenoid valves for supplying air pressure to the microfluidic valves were controlled by a USB interface board. Software was written in Python object-oriented language and used to control the chip manually, operating individual valves, pumps, or sets of valves (called modes). Scripts were written to run complete assays or multiple sets of assays and automatically acquire fluorescence data.
Due to the hydrophobic nature of the PDMS, filling the channels with aqueous solutions was sometimes problematic. Significantly improved fluid flow was observed with the addition of a nonionic detergent, Tween 20 (≤ 0.1%, vol/vol) to the assay buffer. However, small amounts of detergent (0.05% and 0.1% vol/vol) in the assay buffer resulted in a 15% to 20% decrease in released fluorescence intensity. Although optimal results were obtained when 40 mM HEPES (pH 7.6) was used along with 1 mM DTT, the benefits of Tween 20 outweighed the loss of signal. Furthermore, the detergent prevented air from the pneumatic channels from diffusing through the thin PDMS and forming bubbles in the liquid channels.
RESULTS AND DISCUSSION

Biomaterials characterization
Recombinant LC-A. The recombinant protein was purified and finally resuspended in 40 mM HEPES (pH 7.3). To confirm viability of the material, the activity was checked against SNAP-25 substrate. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis under reducing conditions indicated that the cleavage of the substrate had occurred, thus demonstrating enzymatic activity.
Characterization of an internally quenched fluorogenic substrate for BoNT-A. Schmidt and Stafford 10 recently described a fluorogenic substrate (Ac-SNRTRID [dnpK] ANQRA [fluorC] RML-amide) for BoNT-A activity. A comparison of the UV/VIS spectra of the substrate and a synthetic peptide fragment, representing the fluorescent cleavage product Ac-RA (fluorC) RMLamide, was made (data not shown). A peak at 363 nm in the absorbance spectrum of the substrate was observed from dnpK. This peak was clearly absent, as expected, in the cleavage product. A peak observed at 490 nm is due to the fluorescein moiety, which is present in both peptides. Concentration of the fluorescent substrate was determined from the absorbance at 363 nm using Σ = 15,900 M -1 cm -1 for dnpK. In addition, the excitation (λ max 492 nm) and emission (λ max 516 nm) spectra of the intact substrate were measured. 
Macroscale protease activity assay
A macroscale assay using recombinant LC-A was reproduced from published literature. As reported here, cleavage of 2 different internally quenched fluorogenic substrates for recombinant LC-A was observed. Assay results are summarized in Table 1 . Interestingly, it has been reported in the literature that full fluorescence is restored when the SNAPtide ™ substrate is cleaved by the BoNT-A holotoxin, resulting in a 15-fold enhancement of fluorescence. 11 As indicated in Table 1 , the result of 14.7 for the light chain compares favorably with the value reported. 11 Our results using the LC-A thus replicate the observations obtained using the actual holotoxin. In addition, our proteolysis results for the fluoresceinbased substrate compared favorably with reported results. 10 Experiments were conducted to investigate the enzymatic behavior of the light chain. The time course of fluorescence increase due to the proteolytic activity of LC-A was studied. Four enzyme concentrations were used with appropriate substrate control, and the assays were performed at room temperature. The curves follow expected enzyme kinetic behavior. 12 Preliminary kinetic analysis gave encouraging results; second-order linear regression analysis over the time range 0.5 to 3 min (6 data points) for the 4 enzyme curves gave the following ratio of slopes: Heating recombinant LC-A to 95°C for 30 min inactivated the enzyme, similar to observations using BoNT-A toxin. 13 Similarly, DTT in large amounts was also found to inhibit enzymatic activity. The inhibition could be due to binding of the sulfhydryl group to the active site zinc in the LC-A.
Inhibition assay
The primary goal of this study was to demonstrate feasibility of design and fabrication of a scalable, parallelized microfluidic device for conducting complex enzymatic reactions. Hence, it was important to reproduce and establish a known and proven assay at a macroscale that could be used as a benchmark as well as for troubleshooting purposes.
The details of experimental results are as follow. The competitive peptide inhibitor, Ac-CRATKML-amide, of BoNT-A has a sulfhydryl group, and the oxidized form is not inhibitory, so it was dissolved just prior to use in the assay buffer containing freshly prepared 1 mM DTT. The enzyme was incubated with the inhibitor for 30 min at room temperature; the substrate was then added, and the mixture was further incubated for 30 min at room temperature. Results obtained from a microplate-based multisample inhibition assay are shown in Figure 3 , and each data point is the average of reading 3 wells. In this particular macroscale experiment, fluorescence data were obtained at a steady-state time point, in view of the limitations of the microfluidic chip, to obtain initial kinetic data.
Kinetic analysis in macroscale was obtained from plots of initial rates with 3 inhibitor concentrations of 2, 5, and 8 µM and 3 substrate concentrations of 20, 30, and 40 µM. The assay buffer was 40 mM HEPES (pH 7.6) containing 1 mM DTT. The KB iB value for the peptide inhibitor was determined from a Dixon plot and from the equation KB iB = [I]/(KB appB /KB mB ) -1] for a competi- tive inhibitor. Inhibition was evident from the various standard plots of the kinetic data (data not shown). A KB mB of about 14 µM was determined from the data. The KB iB was about 2 to 4 µM, in good agreement with a published value. 14 Figure 4 presents typical results from a macroscale inhibition assay that was conducted in parallel with an assay run on the microfluidic chip. The same reagent concentrations, mixing volume ratios, and mixing protocols in macroscale were used for assays on the microfluidic chip to be consistent. Figure 4 shows that after a 30-min incubation,~40% inhibition of enzymatic activity, compared to controls, was observed in the presence of 40 µM of inhibitor.
Microfluidic device validation
Loading FCP peptide and buffer into the reaction loop of the MIX1 device and operating the pump over a range of conditions validated the operation of the pumps and mixing loops. Fluorescence microscopy was used to measure pumping speed and mixing times. Figure 5 shows the fluorescence signal at a fixed location in the loop for 4 experiments. The signal level rises and falls, resembling a damped sinusoid. The periodicity of the oscillations was used to measure the average velocity of the liquid. The liquids are completely mixed when the oscillations die out. The pump frequency and air pressure were varied to obtain the fastest mixing. Based on these measurements, the MIX1 pumps were operated at 10 Hz and 15 psi when running the assay.
The time to pump the liquid around the loop was measured as the period of oscillation computed by Fourier analysis of the data. The length of the loop divided by the period gave the average linear flow velocity in the channel. As expected, the pumping rate was linear with frequency until the switching speed exceeded the mechanical response of the valves. This point occurred at about 10 Hz, where the velocity was 0.7 mm/sec. At higher speeds, the pumping rate dropped. Nitrogen gas was used to pressurize the reagent reservoirs, providing initial filling of the chip and pumping of the reagents from the reservoirs. The flow velocity was used to estimate the time required for various fluid transfer steps in running an assay.
Results from the BoNT-A assay run on a MIX1 device showed better than 97% reproducibility. The results matching so closely implied that the reagents were sufficiently mixed just after 5 minutes. This agreed with the mixing measurements presented above.
Inhibition assay on the microfluidic device
As in the MIX1 device, the microplate assay was configured for the MIX2 microfluidic device. Results of 4 sequential pairs of assays are shown in Figure 6 and are denoted "left" and "right" for the side of the device on which they were run. Because the device executed assays in parallel, identical sets of reagents were loaded into each half of the chip. In between assays, the chip in its fixture was heated to a temperature of 80 to 90°C for 15 min to denature any residual LC-A from the earlier experiments. Experiments had shown evidence of carryover, and heating the chip eliminated any residual protease activity.
The fluorescence measurements were acquired from a 10-pL measurement volume. The uninhibited reactions and substrate controls represented the signal levels for 0% and 100% inhibition of the recombinant LC-A, respectively. The data showed approximately 40% reduction in enzymatic activity compared to the con- trols, which matched the macroscale results. The run-to-run reproducibility was greater than 90%. Control experiments were performed with substrate alone after all runs to verify that the signal returned to its original levels. A plot of percentage inhibition versus time for the same data set is shown (Fig. 6, inset) . Inhibition is defined here as
Although the assays ran for 45 min and the signals were still rising, the inhibition levels could be determined even at 15 to 20 min.
CONCLUSIONS
A microfluidic screening system for botulinum toxin inhibitors was developed, and a known inhibitor was tested to validate the system. BoNT-A assays were conducted using these chips, and standard inhibition curves were generated. The inhibition results showed agreement with the corresponding experiments done at a macroscale level. Forty percent inhibition was observed in both microscale and macroscale after 30 min of incubation, in the presence of 40 µM inhibitor; however, the kinetics appeared to be different. It is possible that macroscale assays do not translate one-toone at a micro level, and the reaction time courses may not be comparable. It is known that microscale devices have significantly higher ratio of surface area to volume. Hence, any protein adsorption to the PDMS surfaces has a more significant effect on the reaction kinetics.
In addition to demonstrating the functional assays on-chip, the engineering involved creation of a path to multiplexing the assays. The inexpensive molded silicone chips were fabricated on industry-standard 4-inch glass and silicon wafers using established photolithography techniques. The devices had on-chip valves, pumps, and reservoirs for precise control of reagents, and all wetted surfaces were in the disposable chip. As configured here, each assay used 1000-fold less reagents than the same assay run in a 96-well plate (40 nL in microscale vs. 45 µL in macroscale). Metered reagent volumes were determined only by channel geometry (length, width, and depth) and not by flow rates, pressures, or time, and highly accurate photolithography process defined the geometry. Therefore, the reagent volumes were not only radically smaller but also more accurate. The device employed a scalable architecture that, combined with the small footprint of the reaction loop, enables a large number of parallel assays on a single chip. An assay device is under development for conducting 20 assays in parallel; therefore, hundreds of assays can be performed with 1 load of 12 µL of each reagent. Each assay lane, for example, could run a different candidate inhibitor, and a concentration-response matrix could be generated varying both enzyme and inhibitor simultaneously. Although this system was developed for BoNT-A, the microfluidic platform is capable of performing a wide range of fluorometric assays with little or no modification.
